Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 124

1.

A population-based audit of surgical practice and outcomes of oncoplastic breast conservations in Scotland - An analysis of 589 patients.

Romics L, Macaskill EJ, Fernandez T, Simpson L, Morrow E, Pitsinis V, Tovey S, Barber M, Masannat Y, Stallard S, Weiler-Mithoff E, Malyon A, Mansell J, Campbell EJ, Doughty J, Dixon JM.

Eur J Surg Oncol. 2018 Jul;44(7):939-944. doi: 10.1016/j.ejso.2018.04.004. Epub 2018 Apr 13.

PMID:
29705287
2.

Ca2+ signals initiate at immobile IP3 receptors adjacent to ER-plasma membrane junctions.

Thillaiappan NB, Chavda AP, Tovey SC, Prole DL, Taylor CW.

Nat Commun. 2017 Nov 15;8(1):1505. doi: 10.1038/s41467-017-01644-8.

3.

Perianal synovial sarcoma treated postoperatively with Iodine-125 brachytherapy: Technical details.

Tovey S, Stannard C, Maree G, Hiscock R, Thomson C, Panieri E, Goldberg P.

Brachytherapy. 2017 May - Jun;16(3):565-571. doi: 10.1016/j.brachy.2017.02.007. Epub 2017 Mar 30.

PMID:
28365084
4.

Cyclic AMP Recruits a Discrete Intracellular Ca2+ Store by Unmasking Hypersensitive IP3 Receptors.

Konieczny V, Tovey SC, Mataragka S, Prole DL, Taylor CW.

Cell Rep. 2017 Jan 17;18(3):711-722. doi: 10.1016/j.celrep.2016.12.058.

5.

Fluorescence methods for analysis of interactions between Ca(2+) signaling, lysosomes, and endoplasmic reticulum.

Prole DL, López-Sanjurjo CI, Tovey SC, Taylor CW.

Methods Cell Biol. 2015;126:237-59. doi: 10.1016/bs.mcb.2014.10.024. Epub 2015 Jan 16.

PMID:
25665449
6.

Sustained signalling by PTH modulates IP3 accumulation and IP3 receptors through cyclic AMP junctions.

Meena A, Tovey SC, Taylor CW.

J Cell Sci. 2015 Jan 15;128(2):408-20. doi: 10.1242/jcs.163071. Epub 2014 Nov 27.

7.

Rapid recycling of Ca2+ between IP3-sensitive stores and lysosomes.

López Sanjurjo CI, Tovey SC, Taylor CW.

PLoS One. 2014 Oct 22;9(10):e111275. doi: 10.1371/journal.pone.0111275. eCollection 2014.

8.

Reliable encoding of stimulus intensities within random sequences of intracellular Ca2+ spikes.

Thurley K, Tovey SC, Moenke G, Prince VL, Meena A, Thomas AP, Skupin A, Taylor CW, Falcke M.

Sci Signal. 2014 Jun 24;7(331):ra59. doi: 10.1126/scisignal.2005237.

9.

Iodine-125 brachytherapy in the management of squamous cell carcinoma of the oral cavity and oropharynx.

Stannard C, Maree G, Tovey S, Hunter A, Wetter J.

Brachytherapy. 2014 Jul-Aug;13(4):405-12. doi: 10.1016/j.brachy.2014.02.443. Epub 2014 May 10.

PMID:
24818781
10.

Interactions of antagonists with subtypes of inositol 1,4,5-trisphosphate (IP3) receptor.

Saleem H, Tovey SC, Molinski TF, Taylor CW.

Br J Pharmacol. 2014 Jul;171(13):3298-312. doi: 10.1111/bph.12685.

11.

Structural organization of signalling to and from IP3 receptors.

Taylor CW, Tovey SC, Rossi AM, Lopez Sanjurjo CI, Prole DL, Rahman T.

Biochem Soc Trans. 2014 Feb;42(1):63-70. doi: 10.1042/BST20130205. Review.

PMID:
24450629
12.

High-throughput functional assays of IP3-evoked Ca2+ release.

Tovey SC, Taylor CW.

Cold Spring Harb Protoc. 2013 Oct 1;2013(10):930-7. doi: 10.1101/pdb.prot073072.

PMID:
24086049
13.

High-throughput analyses of IP3 receptor behavior.

Taylor CW, Tovey SC, Rossi AM.

Cold Spring Harb Protoc. 2013 Oct 1;2013(10):914-7. doi: 10.1101/pdb.top066100.

PMID:
24086047
14.

Cyclic AMP directs inositol (1,4,5)-trisphosphate-evoked Ca2+ signalling to different intracellular Ca2+ stores.

Tovey SC, Taylor CW.

J Cell Sci. 2013 May 15;126(Pt 10):2305-13. doi: 10.1242/jcs.126144. Epub 2013 Mar 22.

15.

Stimulation of inositol 1,4,5-trisphosphate (IP3) receptor subtypes by adenophostin A and its analogues.

Saleem H, Tovey SC, Riley AM, Potter BV, Taylor CW.

PLoS One. 2013;8(2):e58027. doi: 10.1371/journal.pone.0058027. Epub 2013 Feb 28.

16.

Stimulation of inositol 1,4,5-trisphosphate (IP3) receptor subtypes by analogues of IP3.

Saleem H, Tovey SC, Rahman T, Riley AM, Potter BV, Taylor CW.

PLoS One. 2013;8(1):e54877. doi: 10.1371/journal.pone.0054877. Epub 2013 Jan 25.

17.

Interactions between MAP kinase and oestrogen receptor in human breast cancer.

McGlynn LM, Tovey S, Bartlett JM, Doughty J, Cooke TG, Edwards J.

Eur J Cancer. 2013 Apr;49(6):1176-86. doi: 10.1016/j.ejca.2012.11.020. Epub 2012 Dec 19.

PMID:
23265704
18.

Lysosomes shape Ins(1,4,5)P3-evoked Ca2+ signals by selectively sequestering Ca2+ released from the endoplasmic reticulum.

López-Sanjurjo CI, Tovey SC, Prole DL, Taylor CW.

J Cell Sci. 2013 Jan 1;126(Pt 1):289-300. doi: 10.1242/jcs.116103. Epub 2012 Oct 24.

19.

Confocal microscopy: theory and applications for cellular signaling.

Tovey SC, Brighton PJ, Bampton ET, Huang Y, Willars GB.

Methods Mol Biol. 2013;937:51-93.

PMID:
23007579
20.

Five-year follow-up of participants in a randomised controlled trial showing benefits from exercise for breast cancer survivors during adjuvant treatment. Are there lasting effects?

Mutrie N, Campbell A, Barry S, Hefferon K, McConnachie A, Ritchie D, Tovey S.

J Cancer Surviv. 2012 Dec;6(4):420-30. doi: 10.1007/s11764-012-0233-y. Epub 2012 Jul 27.

21.

Timescales of IP(3)-evoked Ca(2+) spikes emerge from Ca(2+) puffs only at the cellular level.

Thurley K, Smith IF, Tovey SC, Taylor CW, Parker I, Falcke M.

Biophys J. 2011 Dec 7;101(11):2638-44. doi: 10.1016/j.bpj.2011.10.030.

22.

From parathyroid hormone to cytosolic Ca2+ signals.

Taylor CW, Tovey SC.

Biochem Soc Trans. 2012 Feb;40(1):147-52. doi: 10.1042/BST20110615. Review.

PMID:
22260681
23.

Contribution of phosphates and adenine to the potency of adenophostins at the IP₃ receptor: synthesis of all possible bisphosphates of adenophostin A.

Sureshan KM, Riley AM, Thomas MP, Tovey SC, Taylor CW, Potter BV.

J Med Chem. 2012 Feb 23;55(4):1706-20. doi: 10.1021/jm201571p. Epub 2012 Feb 8.

24.

Shorter disease-specific survival of ER-positive breast cancer patients with high cytoplasmic Src kinase expression after tamoxifen treatment.

Elsberger B, Paravasthu DM, Tovey SM, Edwards J.

J Cancer Res Clin Oncol. 2012 Feb;138(2):327-32. doi: 10.1007/s00432-011-1096-8. Epub 2011 Dec 2.

PMID:
22134837
25.

Analysis of IP3 receptors in and out of cells.

Rossi AM, Tovey SC, Rahman T, Prole DL, Taylor CW.

Biochim Biophys Acta. 2012 Aug;1820(8):1214-27. doi: 10.1016/j.bbagen.2011.10.004. Epub 2011 Oct 14. Review.

PMID:
22033379
26.

IP(3) receptors: toward understanding their activation.

Taylor CW, Tovey SC.

Cold Spring Harb Perspect Biol. 2010 Dec;2(12):a004010. doi: 10.1101/cshperspect.a004010. Epub 2010 Oct 27. Review.

27.

Sphingosine kinase 1 induces tolerance to human epidermal growth factor receptor 2 and prevents formation of a migratory phenotype in response to sphingosine 1-phosphate in estrogen receptor-positive breast cancer cells.

Long JS, Edwards J, Watson C, Tovey S, Mair KM, Schiff R, Natarajan V, Pyne NJ, Pyne S.

Mol Cell Biol. 2010 Aug;30(15):3827-41. doi: 10.1128/MCB.01133-09. Epub 2010 Jun 1.

28.

Regulation of inositol 1,4,5-trisphosphate receptors by cAMP independent of cAMP-dependent protein kinase.

Tovey SC, Dedos SG, Rahman T, Taylor EJ, Pantazaka E, Taylor CW.

J Biol Chem. 2010 Apr 23;285(17):12979-89. doi: 10.1074/jbc.M109.096016. Epub 2010 Feb 26.

29.

Is expression or activation of Src kinase associated with cancer-specific survival in ER-, PR- and HER2-negative breast cancer patients?

Elsberger B, Tan BA, Mitchell TJ, Brown SB, Mallon EA, Tovey SM, Cooke TG, Brunton VG, Edwards J.

Am J Pathol. 2009 Oct;175(4):1389-97. doi: 10.2353/ajpath.2009.090273. Epub 2009 Sep 17.

30.

IP3 receptors: some lessons from DT40 cells.

Taylor CW, Rahman T, Tovey SC, Dedos SG, Taylor EJ, Velamakanni S.

Immunol Rev. 2009 Sep;231(1):23-44. doi: 10.1111/j.1600-065X.2009.00807.x. Review.

PMID:
19754888
31.

Synthetic partial agonists reveal key steps in IP3 receptor activation.

Rossi AM, Riley AM, Tovey SC, Rahman T, Dellis O, Taylor EJ, Veresov VG, Potter BV, Taylor CW.

Nat Chem Biol. 2009 Sep;5(9):631-9. doi: 10.1038/nchembio.195. Epub 2009 Aug 9.

32.

Activation of IP(3) receptors by synthetic bisphosphate ligands.

Sureshan KM, Riley AM, Rossi AM, Tovey SC, Dedos SG, Taylor CW, Potter BV.

Chem Commun (Camb). 2009 Mar 14;(10):1204-6. doi: 10.1039/b819328b. Epub 2009 Feb 4.

33.

Ras/Raf-1/MAPK pathway mediates response to tamoxifen but not chemotherapy in breast cancer patients.

McGlynn LM, Kirkegaard T, Edwards J, Tovey S, Cameron D, Twelves C, Bartlett JM, Cooke TG.

Clin Cancer Res. 2009 Feb 15;15(4):1487-95. doi: 10.1158/1078-0432.CCR-07-4967.

34.

Poor survival outcomes in HER2-positive breast cancer patients with low-grade, node-negative tumours.

Tovey SM, Brown S, Doughty JC, Mallon EA, Cooke TG, Edwards J.

Br J Cancer. 2009 Mar 10;100(5):680-3. doi: 10.1038/sj.bjc.6604940. Epub 2009 Feb 17.

35.

Phosphorylated c-Src in the nucleus is associated with improved patient outcome in ER-positive breast cancer.

Campbell EJ, McDuff E, Tatarov O, Tovey S, Brunton V, Cooke TG, Edwards J.

Br J Cancer. 2008 Dec 2;99(11):1769-74. doi: 10.1038/sj.bjc.6604768. Epub 2008 Nov 18.

36.

Selective coupling of type 6 adenylyl cyclase with type 2 IP3 receptors mediates direct sensitization of IP3 receptors by cAMP.

Tovey SC, Dedos SG, Taylor EJ, Church JE, Taylor CW.

J Cell Biol. 2008 Oct 20;183(2):297-311. doi: 10.1083/jcb.200803172.

37.

Lack of receptor-selective effects of either RGS2, RGS3 or RGS4 on muscarinic M3- and gonadotropin-releasing hormone receptor-mediated signalling through G alpha q/11.

Karakoula A, Tovey SC, Brighton PJ, Willars GB.

Eur J Pharmacol. 2008 Jun 10;587(1-3):16-24. doi: 10.1016/j.ejphar.2008.03.047. Epub 2008 Apr 4.

PMID:
18457830
38.

Expression of tumor necrosis factor alpha converting enzyme in endocrine cancers.

Kirkegaard T, Naresh A, Sabine VS, Tovey SM, Edwards J, Dunne B, Cooke TG, Jones FE, Bartlett JM.

Am J Clin Pathol. 2008 May;129(5):735-43. doi: 10.1309/N6YB6YDVF58YCNHN.

PMID:
18426733
39.

Genetic alterations of CCND1 and EMSY in breast cancers.

Kirkegaard T, Nielsen KV, Jensen LB, Campbell FM, Müller S, Tovey SM, Brown S, Cooke TG, Bartlett JM.

Histopathology. 2008 May;52(6):698-705. doi: 10.1111/j.1365-2559.2008.03007.x. Epub 2008 Apr 2.

PMID:
18393977
40.

2-Position base-modified analogues of adenophostin A as high-affinity agonists of the D-myo-inositol trisphosphate receptor: in vitro evaluation and molecular modeling.

Sureshan KM, Trusselle M, Tovey SC, Taylor CW, Potter BV.

J Org Chem. 2008 Mar 7;73(5):1682-92. doi: 10.1021/jo702617c. Epub 2008 Feb 2.

PMID:
18247493
41.

How does intracellular Ca2+ oscillate: by chance or by the clock?

Skupin A, Kettenmann H, Winkler U, Wartenberg M, Sauer H, Tovey SC, Taylor CW, Falcke M.

Biophys J. 2008 Mar 15;94(6):2404-11. Epub 2007 Dec 7.

42.

Rapid functional assays of intracellular Ca2+ channels.

Tovey SC, Sun Y, Taylor CW.

Nat Protoc. 2006;1(1):259-63.

PMID:
17406242
43.

Amplified in breast cancer 1 in human epidermal growth factor receptor - positive tumors of tamoxifen-treated breast cancer patients.

Kirkegaard T, McGlynn LM, Campbell FM, Müller S, Tovey SM, Dunne B, Nielsen KV, Cooke TG, Bartlett JM.

Clin Cancer Res. 2007 Mar 1;13(5):1405-11.

44.

Bad expression predicts outcome in patients treated with tamoxifen.

Cannings E, Kirkegaard T, Tovey SM, Dunne B, Cooke TG, Bartlett JM.

Breast Cancer Res Treat. 2007 Apr;102(2):173-9. Epub 2006 Sep 27.

PMID:
17004114
45.

Low expression of HER2 protein in breast cancer is biologically significant.

Tovey SM, Reeves JR, Stanton P, Ozanne BW, Bartlett JM, Cooke TG.

J Pathol. 2006 Nov;210(3):358-62.

PMID:
16981252
46.

Synthesis of adenophostin A analogues conjugating an aromatic group at the 5'-position as potent IP3 receptor ligands.

Mochizuki T, Kondo Y, Abe H, Tovey SC, Dedos SG, Taylor CW, Paul M, Potter BV, Matsuda A, Shuto S.

J Med Chem. 2006 Sep 21;49(19):5750-8.

PMID:
16970399
47.

Signalling from parathyroid hormone.

Tovey SC, Dedos SG, Taylor CW.

Biochem Soc Trans. 2006 Aug;34(Pt 4):515-7. Review.

PMID:
16856848
48.

Ca2+ entry through plasma membrane IP3 receptors.

Dellis O, Dedos SG, Tovey SC, Taufiq-Ur-Rahman, Dubel SJ, Taylor CW.

Science. 2006 Jul 14;313(5784):229-33.

49.

The ERBB4/HER4 intracellular domain 4ICD is a BH3-only protein promoting apoptosis of breast cancer cells.

Naresh A, Long W, Vidal GA, Wimley WC, Marrero L, Sartor CI, Tovey S, Cooke TG, Bartlett JM, Jones FE.

Cancer Res. 2006 Jun 15;66(12):6412-20.

50.

Guanophostin A: Synthesis and evaluation of a high affinity agonist of the D-myo-inositol 1,4,5-trisphosphate receptor.

Sureshan KM, Trusselle M, Tovey SC, Taylor CW, Potter BV.

Chem Commun (Camb). 2006 May 21;(19):2015-7. Epub 2006 Mar 31.

PMID:
16767260

Supplemental Content

Support Center